Pharmaceuticals, intellectual property and free-trade: The case of the US-Australia free trade agreement

Peter Drahos, Buddhima Lokuge, Thomas Alured Faunce, Martyn Goddard, David Henry

Research output: Contribution to journalArticleResearchpeer-review

32 Citations (Scopus)

Abstract

Australia did poorly in several key areas of the recently completed free trade agreement with the US. It failed to insulate the Pharmaceutical Benefits Scheme (PBS) from significant change, and conceded to increased intellectual property standards. The PBS, as a system of effective bargaining with multinational pharmaceutical firms, has been deeply compromised and higher drug prices can be expected over time. The intellectual property chapter strengthens the position of patent owners and undermines the evolution of a competitive generics industry. These developments are part of a broader and internationally coordinated strategy being pursued by pharmaceutical multinationals to globalize and strengthen patent rights and monopoly profits.

Original languageEnglish
Pages (from-to)243-257
Number of pages15
JournalPrometheus (United Kingdom)
Volume22
Issue number3
DOIs
Publication statusPublished - 2004
Externally publishedYes

Fingerprint

free trade
intellectual property
pharmaceutical
drug
patent
monopoly
bargaining
profit
firm
industry

Cite this

Drahos, Peter ; Lokuge, Buddhima ; Faunce, Thomas Alured ; Goddard, Martyn ; Henry, David. / Pharmaceuticals, intellectual property and free-trade : The case of the US-Australia free trade agreement. In: Prometheus (United Kingdom). 2004 ; Vol. 22, No. 3. pp. 243-257.
@article{700e5985298944b49616b1bc6865748b,
title = "Pharmaceuticals, intellectual property and free-trade: The case of the US-Australia free trade agreement",
abstract = "Australia did poorly in several key areas of the recently completed free trade agreement with the US. It failed to insulate the Pharmaceutical Benefits Scheme (PBS) from significant change, and conceded to increased intellectual property standards. The PBS, as a system of effective bargaining with multinational pharmaceutical firms, has been deeply compromised and higher drug prices can be expected over time. The intellectual property chapter strengthens the position of patent owners and undermines the evolution of a competitive generics industry. These developments are part of a broader and internationally coordinated strategy being pursued by pharmaceutical multinationals to globalize and strengthen patent rights and monopoly profits.",
author = "Peter Drahos and Buddhima Lokuge and Faunce, {Thomas Alured} and Martyn Goddard and David Henry",
year = "2004",
doi = "10.1080/0810902042000255705",
language = "English",
volume = "22",
pages = "243--257",
journal = "Prometheus",
issn = "0810-9028",
publisher = "Routledge",
number = "3",

}

Pharmaceuticals, intellectual property and free-trade : The case of the US-Australia free trade agreement. / Drahos, Peter; Lokuge, Buddhima; Faunce, Thomas Alured; Goddard, Martyn; Henry, David.

In: Prometheus (United Kingdom), Vol. 22, No. 3, 2004, p. 243-257.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Pharmaceuticals, intellectual property and free-trade

T2 - The case of the US-Australia free trade agreement

AU - Drahos, Peter

AU - Lokuge, Buddhima

AU - Faunce, Thomas Alured

AU - Goddard, Martyn

AU - Henry, David

PY - 2004

Y1 - 2004

N2 - Australia did poorly in several key areas of the recently completed free trade agreement with the US. It failed to insulate the Pharmaceutical Benefits Scheme (PBS) from significant change, and conceded to increased intellectual property standards. The PBS, as a system of effective bargaining with multinational pharmaceutical firms, has been deeply compromised and higher drug prices can be expected over time. The intellectual property chapter strengthens the position of patent owners and undermines the evolution of a competitive generics industry. These developments are part of a broader and internationally coordinated strategy being pursued by pharmaceutical multinationals to globalize and strengthen patent rights and monopoly profits.

AB - Australia did poorly in several key areas of the recently completed free trade agreement with the US. It failed to insulate the Pharmaceutical Benefits Scheme (PBS) from significant change, and conceded to increased intellectual property standards. The PBS, as a system of effective bargaining with multinational pharmaceutical firms, has been deeply compromised and higher drug prices can be expected over time. The intellectual property chapter strengthens the position of patent owners and undermines the evolution of a competitive generics industry. These developments are part of a broader and internationally coordinated strategy being pursued by pharmaceutical multinationals to globalize and strengthen patent rights and monopoly profits.

UR - http://www.scopus.com/inward/record.url?scp=4644226808&partnerID=8YFLogxK

U2 - 10.1080/0810902042000255705

DO - 10.1080/0810902042000255705

M3 - Article

VL - 22

SP - 243

EP - 257

JO - Prometheus

JF - Prometheus

SN - 0810-9028

IS - 3

ER -